> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# IntelGenx Resubmits NDA for Migraine Drug
- URL: https://www.fdaweb.com/intelgenx-resubmits-nda-for-migraine-drug/
- Published: 2019-10-22T12:00:00.000Z
- Updated: 2026-09-15T01:58:06.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5145308

FDA has accepted for review an IntelGenx 505(b)(2) NDA resubmission for Rizaport VersaFilm (rizatriptan ) an oral disintegrating film for treating acute migraine. Rizatriptan is the active ingredient in Merck’s migraine drug Maxalt-MLT. IntelGenx says the selective 5-HT1B/1D receptor agonist demonstrates the highest efficacy and exhibits the shortest Tmax providing quick onset of action for migraine sufferers compared to other triptan-based oral medications. FDA has a set a user fee review action target date of 3/26/2020.